Everything below concerns research peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-05. Numbers and descriptions here follow the published literature rather than marketing material.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
== Further reading == Aird, William C. "Blood Endothelial Cells" in Endothelial Cells In Health and Disease. Boca Raton: Taylor & Francis, 2005. Milosevic, V., Edelmann, R.J., Fosse, J.H., Östman, A., Akslen, L.A. (2022). Molecular Phenotypes of Endothelial Cells in Malignant Tumors. In: Akslen, L.A., Watnick, R.S. (eds) Biomarkers of the Tumor Microenvironment. Springer, Cham. https://doi.org/10.1007/978-3-030-98950-7_3 Stem Cells, Therapeutic Applications by Mariusz Z. Ratajczak Advances in Experimental Medicine and Biology
Small, hand-pumped reverse osmosis filters were originally developed for the military in the late 1980s for use as survival equipment, for example, to be included with inflatable rafts on aircraft. Civilian versions are available. Instead of using the static pressure of a water supply line to force the water through the filter, pressure is provided by a hand-operated pump. These devices can generate drinkable water from seawater. The Portable Aqua Unit for Lifesaving ("PAUL") is a portable ultrafiltration-based membrane water filter for humanitarian aid. It allows the decentralized supply of clean water in emergency and disaster situations for about 400 persons per unit per day. The filter is designed to function with neither chemicals nor energy nor trained personnel.
=== Diabetes === In contrast to previous studies, a recent study of streptozotocin-induced and high-fat diet-induced murine models of diabetes found that the FFAR3-activating drug, AR420626, increased blood plasma insulin levels and stimulated skeletal muscle to take up glucose and thereby improved glucose tolerance test results. Other recent studies have reported that activated FFAR3 may reduce, increase, or have little effect on insulin secretion depending on 1) the levels of ambient glucose and FFAR3 activators studied, (2) human or animal species studied, (3) age of the animals studied, and (4) variations in the proportions of alpha, beta, and delta cells in the pancreatic islets of humans. The role of FFAR3 in human as well as animal models of insulin secretion and diabetes requires further studies.
=== Protein identification === Mass spectrometry and microarray produce peptide fragmentation information but do not give identification of specific proteins present in the original sample. Due to the lack of specific protein identification, past researchers were forced to decipher the peptide fragments themselves. However, there are currently programs available for protein identification. These programs take the peptide sequences output from mass spectrometry and microarray and return information about matching or similar proteins. This is done through algorithms implemented by the program which perform alignments with proteins from known databases such as UniProt and PROSITE to predict what proteins are in the sample with a degree of certainty.
=== Assembly === Ribosomal RNA's integration and assembly into ribosomes begins with their folding, modification, processing and assembly with ribosomal proteins to form the two ribosomal subunits, the LSU and the SSU. In Prokaryotes, rRNA incorporation occurs in the cytoplasm due to the lack of membrane-bound organelles. In Eukaryotes, however, this process primarily takes place in the nucleolus and is initiated by the synthesis of pre-RNA. This requires the presence of all three RNA polymerases. In fact, the transcription of pre-RNA by RNA polymerase I accounts for about 60% of cell's total cellular RNA transcription. This is followed by the folding of the pre-RNA so that it can be assembled with ribosomal proteins. This folding is catalyzed by endo- and exonucleases, RNA helicases, GTPases and ATPases. The rRNA subsequently undergoes endo- and exonucleolytic processing to remove external and internal transcribed spacers. The pre-RNA then undergoes modifications such as methylation or pseudouridinylation before ribosome assembly factors and ribosomal proteins assemble with the pre-RNA to form pre-ribosomal particles. Upon going under more maturation steps and subsequent exit from the nucleolus into the cytoplasm, these particles combine to form the ribosomes. The basic and aromatic residues found within the primary structure of rRNA allow for favorable stacking interactions and attraction to ribosomal proteins, creating a cross-linking effect between the backbone of rRNA and other components of the ribosomal unit.
Sources: en.wikipedia.org
== Career == Working first in the Physical Chemistry Laboratory, he moved to the Dunn Nutritional Laboratory, and in 1938 moved to Wool Industries Research Institution in Leeds. He was head of the biochemistry division of Boots Pure Drug Company from 1946 to 1948, when he joined the Medical Research Council. There, he was appointed head of the physical chemistry division of the National Institute for Medical Research in 1952, and was chemical consultant from 1956 to 1959. He specialised in biochemistry, in some aspects of vitamins E and B2, and in techniques that laid the foundation for several new types of chromatography. He developed partition chromatography whilst working on the separation of amino acids, and later developed gas-liquid chromatography with Anthony T. James. Amongst many honours, he received his Nobel Prize in 1952. After his retirement from the University of Sussex, he was visiting professor at both the University of Houston in Texas and the EPFL (École Polytechnique Fédérale de Lausanne) in Switzerland. He published far fewer papers than the typical Nobel winners—only 70 in all—but his ninth paper contained the work that would eventually win him the Nobel Prize. The University of Houston dropped him from its chemistry faculty in 1979 (when he was 69 years old) because he was not publishing enough.
== Partnerships and Agreements == Licensing agreements for Biomatrica technologies were signed with Qiagen in 2007 and 2009. Following the launch of DNAstable, the company gained the interest of law enforcement organizations, such as the California Department of Justice, which sought to stabilize DNA samples from crime scenes for forensics purposes. Other law enforcement organizations, including sheriffs’ departments in Orange County, CA Los Angeles, CA, and Palm Beach, FL, have adopted ambient temperature forensic sample management systems based on Biomatrica's technologies. Also in 2010, Biomatrica signed a collaborative research and development agreement (CRADA) with United States Army Medical Research Institute for Infectious Diseases (USAMRIID) to develop and test new technologies for ambient temperature stabilization of clinical and biological samples. The same year, Biomatrica began a partnership agreement with the U.S. National Cancer Institute (NCI) for biomarker stabilization and SAIC-Frederick to improve molecular analysis of tumors. In 2011, the company announced a partnership agreement with In-Q-Tel, an investment firm that identifies technologies to support the mission of the U.S. intelligence community. In 2014, Biomatrica and American Type Tissue Culture (ATCC) signed a licensing agreement for Biomatrica to supply its DNA & RNA stabilization reagents to the ATCC for use in the latter company's DNA and RNA standards. In the same year, Biomatrica and Sigma-Aldrich signed an agreement for the worldwide distribution of Biomatrica's stabilization reagents.
The aim of the partnership is to combine both technologies in a bio-artificial pancreas device, which releases insulin in response to blood glucose levels, to bring to clinical trial stages. The San Diego, California based biotech company ViaCyte has also developed a product aiming to provide a solution for type 1 diabetes which uses an encapsulation device made of a semi-permeable immune reaction-protective membrane. The device contains pancreatic progenitor cells that have been differentiated from embryonic stem cells. After surgical implantation in an outpatient procedure, the cells mature into endocrine cells which arrange in islet-like clusters and mimic the function of the pancreas, producing insulin and glucagon. The technology advanced from pre-clinical studies to FDA approval for phase 1 clinical trials in 2014, and presented two-year data from the trial in June 2018. They reported that their product, called PEC-Encap, has so far been safe and well tolerated in patients at a dose below therapeutic levels. The encapsulated cells were able to survive and mature after implantation, and immune system rejection was decreased due to the protective membrane. The second phase of the trial will evaluate the efficacy of the product. ViaCyte has also been receiving financial support from JDRF on this project.
Little prolactin—the predominant form. It has a molecular weight of approximately 23-kDa. It is a single-chain polypeptide of 199 amino acids and is apparently the result of removal of some amino acids. Big prolactin—approximately 48 kDa. It may be the product of interaction of several prolactin molecules. It appears to have little, if any, biological activity. Macroprolactin—approximately 150 kDa. It appears to have a low biological activity. Other variants with the molecular masses of 14, 16, and 22 kDa. The levels of larger ones are somewhat higher during the early postpartum period.
=== Horny goat weed === Horny goat weed (Epimedii herba) is used in Chinese folk medicine. It was thought to be useful for treating medical conditions and improving sexual desire, sexual pleasure, and/or sexual behavior. Horny goat weed contains icariin, a flavanol glycoside. Its exotic name comes from the tendency of goats in the region to seek out this weed. Once farmers saw its effects on the goat population they began to use it to increase the number of workers on their farms.
Sources: en.wikipedia.org
Einstein Bros. Bagels is an American chain of bagel cafes. In the 1990s, the company bought out several retail bagel chains from regions around the US which lacked bagel traditions. After filing for bankruptcy in 2000, the company was bought out by New World Coffee. It became part of Panera Brands in August 2021.
=== Market === The market for garlic powder can be split into multiple segments based on source, packaging, end use and distribution channels. The key market players in the garlic powder industry include some of the world's most renowned manufacturers and suppliers, such as McCormick & Company, Garlico, Masterfoods, and Amazon. China is the largest producer of garlic powder, followed by India, with both countries consuming garlic powder as part of their native cuisines and having hundreds of their own internal suppliers within the countries.
=== Topical and procedural therapies === Topical therapies are used mainly for cosmetic reasons. Small clinical studies have reported improvement with topical retinoids, urea preparations and other keratolytic agents, although evidence remains limited and results vary among individuals. Topical treatment does not modify the underlying cause of AN. Procedural interventions, including fractional carbon dioxide (CO2) laser and various chemical peels, have been explored in pilot studies and small comparative trials. A randomized controlled trial involving 38 participants reported that fractional CO2 laser resulted in greater reduction of lesion severity compared with retinoic-acid peel; however, the study was short-term and limited in size. Procedural therapies generally require specialised equipment, and availability and cost may limit use.
(WINNER) The contestant won the whole competition. (WIN) The contestant won the Main Heat challenge. (HIGH) The contestant had one of the best dishes for that week. (IN) The contestant performed well enough to move on to the next week. (LOW) The contestant had one of the bottom dishes for that week, but was not eliminated. (OUT) The contestant was eliminated for worst dish.
=== Rock Bottom Restaurant Breweries === The company operates 16 breweries under the name Rock Bottom Restaurant & Brewery. These breweries are located in several states, with five restaurants in Colorado, five in Illinois and one restaurant each in California, Florida, Maryland, Massachusetts, Minnesota and Virginia. The store was renamed Rock Bottom after someone pointed out that they were "building at the bottom of the rock," which was Prudential's slogan at the time. In 2000, the Boston-based Brew Moon Enterprises Inc. filed for bankruptcy and sold four of its five restaurant-microbreweries to Rock Bottom. In 2009, the La Jolla location in San Diego won a medal at the Great American Beer Festival, and in 2012 they medaled at the World Beer Cup. Rock Bottom Restaurants won Brewpub Group Brewer of the Year award at the 2013 Great American Beer Festival (GABF).
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
The standard approach is reverse-phase high-performance liquid chromatography, reported as a percentage of total peak area. Because that figure alone says little about the nature of the impurities, the accompanying chromatogram is normally the more useful document for judging a batch.